Merck
CN
  • Acetylation at lysine 346 controls the transforming activity of the HTLV-1 Tax oncoprotein in the Rat-1 fibroblast model.

Acetylation at lysine 346 controls the transforming activity of the HTLV-1 Tax oncoprotein in the Rat-1 fibroblast model.

Retrovirology (2013-07-25)
Julie Lodewick, Carla Sampaio, Mathieu Boxus, Anne-Sophie Rinaldi, Katia Coulonval, Luc Willems, Pierre P Roger, Françoise Bex
摘要

Transformation by the Tax oncoprotein of the human T cell leukemia virus type 1 (HTLV-1) is governed by actions on cellular regulatory signals, including modulation of specific cellular gene expression via activation of signaling pathways, acceleration of cell cycle progression via stimulation of cyclin-dependent kinase activity leading to retinoblastoma protein (pRb) hyperphosphorylation and perturbation of survival signals. These actions control early steps in T cell transformation and development of Adult T cell leukemia (ATL), an aggressive malignancy of HTLV-1 infected T lymphocytes. Post-translational modifications of Tax by phosphorylation, ubiquitination, sumoylation and acetylation have been implicated in Tax-mediated activation of the NF-κB pathway, a key function associated with Tax transforming potential. In this study, we demonstrate that acetylation at lysine K(346) in the carboxy-terminal domain of Tax is modulated in the Tax nuclear bodies by the acetyltransferase p300 and the deacetylases HDAC5/7 and controls phosphorylation of the tumor suppressor pRb by Tax-cyclin D3-CDK4-p21(CIP) complexes. This property correlates with the inability of the acetylation deficient K(346)R mutant, but not the acetylation mimetic K(346)Q mutant, to promote anchorage-independent growth of Rat-1 fibroblasts. By contrast, acetylation at lysine K(346) had no effects on the ability of Tax carboxy-terminal PDZ-binding domain to interact with the tumor suppressor hDLG. The identification of the acetyltransferase p300 and the deacetylase HDAC7 as enzymes modulating Tax acetylation points to new therapeutic targets for the treatment of HTLV-1 infected patients at risk of developing ATL.

材料
货号
品牌
产品描述

Sigma-Aldrich
L -赖氨酸, ≥98% (TLC)
Sigma-Aldrich
L-赖氨酸 单盐酸盐, reagent grade, ≥98% (HPLC)
Sigma-Aldrich
L-赖氨酸 单盐酸盐, from non-animal source, meets EP, JP, USP testing specifications, suitable for cell culture, 98.5-101.0%
Sigma-Aldrich
L -赖氨酸, crystallized, ≥98.0% (NT)
Supelco
L-赖氨酸 单盐酸盐, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
L-赖氨酸 单盐酸盐, BioUltra, ≥99.5% (AT)
Supelco
L-赖氨酸 单盐酸盐, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland
Sigma-Aldrich
L-赖氨酸 乙酸盐, ≥98% (HPLC)
Supelco
L-赖氨酸乙酸盐, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
L -赖氨酸, Vetec, reagent grade, ≥98%